Keliomics’ Post

Our work to develop a new treatment that can provide much-needed relief for #AtopicDermatitis is rooted in a deep understanding of #CellBiology. Dr. Martin Dahl, SVP of Research, shares an update on preclinical research evaluating our investigational #BTLAAgonist, which has been shown to reduce broad T cell-driven #inflammation and modulate #DendriticCell function.     #Innovation #ClinicalDermatology #ClinicalResearch 

Digital innovation in health sector is more challenging than others. Sensor-based #wearable #DHTs have the potential to meet the unmet measurement needs in clinical development. But for the industry to fully realize the opportunities, collaboration is key.  👤Recruiting our first patient in the #DECODE #nocturnalscratch working group study is an important milestone in our effort to generate the evidence and demonstrate the efficacy and performance of a DHT-derived measure to fill these gaps. This is one example of pre-competitive partnership to deliver fit-for-purpose digital technologies for #patientcentric measures. 

🚀 We are thrilled to announce the newest additions to our Scientific Advisory Board! Please join us in welcoming Mary Spellman M.D. and Cees (Cornelis) Wortel, MD, PhD to the team. Dr. Spellman is a board-certified dermatologist with over 30 years of experience and a deep expertise in collaborating with the FDA on novel clinical endpoints. Dr. Wortel, a seasoned executive and founder of Clinquest, brings extensive knowledge in immunology and autoimmune diseases, having played a key role in the development of groundbreaking treatments like Remicade. Our commitment to excellence, coupled with the unique insights of our expanded advisory board, makes Catawba Research the definitive choice for companies seeking to achieve extraordinary outcomes in their clinical trials. We look forward to the incredible impact they will have on our work! 𝗥𝗲𝗮𝗱 𝘁𝗵𝗲 𝗽𝗿𝗲𝘀𝘀 𝗿𝗲𝗹𝗲𝗮𝘀𝗲: https://lnkd.in/emH6wPfH 𝗠𝗲𝗲𝘁 𝘁𝗵𝗲 𝗿𝗲𝘀𝘁 𝗼𝗳 𝗼𝘂𝗿 𝗦𝗰𝗶𝗲𝗻𝘁𝗶𝗳𝗶𝗰 & 𝗥𝗲𝗴𝘂𝗹𝗮𝘁𝗼𝗿𝘆 𝗔𝗱𝘃𝗶𝘀𝗼𝗿𝘀: https://lnkd.in/dFar47R #CatawbaResearch #RegulatoryApproval #FDA #ClinicalTrials #GlobalResearch #ExcellenceInScience #Innovation #clinicalresearch #dermatology #immunology #autoimmune #clinicalresearch #science #scientific #CRO #contractresearchorganization

Advances occur in little steps. Once in a while, we see a leap. The recent publication of the results of a phase 2 study evaluating an oral IL-23 receptor antagonist peptide for #plaquepsoriasis by Bissonnette et al is a leap forward. The leap is not that the drug works – we have known for some time that the 23-17 axis is central to the pathogenesis of #psoriasis (JID 2012; 132:2466-2469 . Note: the study, NCT00867100, completed in 2009 / NEJM 2017; 376:1551-1560 , NCT02054481 completed in 2015 ). The leap is two footed. There is always unmet needs. Exploring an orally administered therapy will increase the options and opportunities for patients. Does size really matter? We have an opportunity to explore the potential for therapeutic differences between small and large molecules. A three point landing is plausible - an opportunity to tease out differences between blocking a ligand and blocking the associated receptor. I can hardly wait for the next steps and the next great leaps. #clinicalresearch #clinicalstudies #clinicaltrials #dermatology

😉 ETAP-Lab at a glimpse 💡Did you know? ETAP-Lab is made of 3 laboratories of excellence offering pharmacology and preclinical research services, as well as scientific expertise, to the pharmaceutical and biotech industries.   👩🔬👨🔬Our specialists advise and support you in #Dermatology, #Cardiology and #Neurology (specifically in neurodegenerative diseases, stroke and psychopharmacology).   🔔Follow ETAP-Lab - Preclinical Efficacy CRO, #StrokAlliance and SYNCROSOME - Cardiovascular Preclinical expert to cover all the group's activities.   ➡️ Keep up to date with scientific news in our specialty areas and our latest preclinical models ➡️ Meet our experts at conferences around the world ➡️ Discover the progress of our research and innovation programs   #preclinicalresearch #MadeInFrance #healthtech

🔬 Science Corner (8th Edition): 💉 Phase 1: Our Breakthrough Begins  Let's discuss the design of Cytonics Corporation's imminent Phase 1 study, what clinical data we will collect, and what it means for the future of the company and your investment. 🔍 What We Will Do Our upcoming trial will enroll 20 participants across three distinguished clinical sites. The study is structured to include two distinct groups: ➡️ Treatment Group: 10 patients will receive two doses of CYT-108, administered three months apart. ➡️ Control Group: 10 patients will receive a saline placebo following the same schedule. Post-administration, all participants will undergo a rigorous three-month follow-up period. 👀 What We Will Look For  The primary goal of this phase is to evaluate the safety and tolerability of CYT-108. However, the scope of our study extends beyond just safety: ✅ Efficacy Assessment: The effectiveness of CYT-108 will be measured using the WOMAC (Western Ontario and McMaster Universities Arthritis Index) score, which assesses pain, stiffness, and physical function in osteoarthritis patients. ✅ Disease Modification: A crucial component of our trial involves the ARGS assay, a biomarker assay that detects fragments specifically cleaved from aggrecan (a key cartilage component) by the aggrecanases, enzymes active in osteoarthritis. This assay will help us identify potential disease-modifying effects of CYT-108, an aspect seldom addressed by current therapies. Read the full synopsis here: https://lnkd.in/ePw5pj5V #biotechnology #arthritis #osteoarthritis #investing #crowdfunding #venturecapital #healthcare #drugdevelopment #clinicaltrials #regenerativemedicine #orthopedics #orthopaedics #surgery #investor #FDA #medicine #lifesciences #researchanddevelopment #capitalmarkets

We are thrilled to announce a remarkable breakthrough achieved by the esteemed Department of Biochemistry and Molecular Medicine at The George Washington University School of Medicine and Health Sciences. Their groundbreaking research has made a significant advancement in the management of dermatological side effects associated with Erlotinib, a key anti-tumorigenic agent used in treating various cancers.   This development, detailed in a recent study “Topical Application of Aprepitant Inhibits Erlotinib-induced Facial Dermatitis/Hair Loss” in the Journal of Dermatology and Skin Science led by Dr. William Weglicki, Iu Tong Mak, jay kramer, Joanna Chmielinska, examined the adverse skin effects of Erlotinib with a primary focus on its propensity to trigger severe facial rash and hair loss.   Dr. Weglicki and team uncovered that these challenging side effects are mediated by substance P, a neuropeptide. By implementing the targeted topical application of Aprepitant, a substance known to effectively block substance P receptor, a remarkable reduction of up to 70% in these detrimental side effects can be achieved as demonstrated in the rat models.   Read More: https://lnkd.in/exjzdDsd   This transformative discovery marks a pivotal milestone in enhancing the quality of life for patients undergoing cancer treatment by effectively addressing one of Erlotinib therapy’s most distressing side effects. Our pride in this breakthrough is immense, as it heralds a new chapter in making cancer therapy more tolerable for patients.   #CancerTreatment #Erlotinib #DermatologicalSideEffects #Aprepitant #GeorgeWashingtonUniversity #MedicalResearch #InnovativeHealthcare #gwu #gwsmhs #gwresearch #gwsph

Are you exploring treatment options for Atopic Dermatitis, Psoriasis or Sarcoidosis? GENEActiv can add significant value to your clinical research as it can detect and quantify fine motor movements which can provide valuable insight into the effectiveness of treatments. Unlock the potential to understand treatment impacts like never before: https://lnkd.in/duSrnRDu #DermatologyResearch #ClinicalTrials

Are you exploring treatment options for Atopic Dermatitis, Psoriasis or Sarcoidosis? GENEActiv can add significant value to your clinical research as it can detect and quantify fine motor movements which can provide valuable insight into the effectiveness of treatments. Unlock the potential to understand treatment impact: https://lnkd.in/eW3fYH76 #DermatologyResearch #ClinicalTrials

This is an interesting list of how top Pharma companies are innovating referred by their drug pipelines! It also shows how the companies are spread across different countries with US dominating the list with 6 companies Pfizer, Eli Lilly, BMS , J&J, Merck and Abbvie, Switzerland with two key players Roche and Novartis, UK with two giants Astra Zeneca and GSK and two from Asia Pacific with Takeda from Japan and Hengrui from China.